 |
|
Become an MS Research Champion How We Will Stop MS (.pdf) |
There are more potential MS therapies in development today than at any other time in history, and a variety of therapies exist, largely for those with relapsing forms of multiple sclerosis.
For some, these treatments reduce the number and severity of attacks and slow disease activity, but more must be done to stop disease progression for everyone affected by MS – including those with progressive forms.
We must find ways to stop all disease activity and prevent further progression for those who already have MS. Here’s how:
- We must better understand the role the immune system plays in the cause of MS and in ongoing disease activity
- We must pursue research leading toward clinical trials of new therapies to stop damage and progression of disability
- We must ensure that we understand health care issues and gather data to advocate for policies that enable everyone with MS to access quality care and treatment
- We must understand the mechanisms that cause tissue injury and that drive disease progression.
Intriguing Leads on the Horizon
Research News
Clinical Trials
Researchers Need You
How Far We’ve Come
For Researchers
Research We Fund
News Related to Stopping MS
Latest results about emerging MS therapies, risk factors, disease mechanisms, rehabilitation, CCSVI, and much more presented at AAN Meeting
May 16, 2012
Nearly 12,000 neurologists and investigators convened in New Orleans in April to present findings at the American Academy of Neurology’s annual meeting. Over 500 scientific presentations and display posters focused on research to stop MS, restore function, and end MS forever. The MS sessions were often standing-room only, and appear to get bigger every year. Among these were the latest results from pivotal clinical trials of emerging MS therapies, possible risk factors, underlying disease mechanisms, rehabilitation approaches, CCSVI, and much more.
Study finds that virus naturally found in human genes to be active on immune cells in some people with active MS
Mar 21, 2012
A new study by Dr. Magdalena Laska (Aarhuis University, Denmark) and colleagues suggests that components of a virus called HERV-Fc1, which are derived from genes normally found in the DNA of all humans, are present at higher levels in plasma and on immune cells in people with active MS. The study, published recently online in the Journal of Virology, provides an intriguing lead to a factor may either cause or result from immune attacks in MS or other disorders. Further research will be needed to better define the unknown role of this factor and its possible implications for people with MS.
Study: Woman’s Risk of Having a First Neurologic Event, Which Often Leads to MS, Decreased with Increased Number of Pregnancies
Mar 07, 2012
Women’s risk for developing clinically isolated syndrome, which often leads to multiple sclerosis, was shown to decrease with increased number of pregnancies in a comprehensive study undertaken in Australia. Clinically isolated syndrome (CIS) is a first neurologic episode caused by inflammation or damage to nerve fiber-insulating myelin in the brain or spinal cord. Although the results of this Ausimmune Study need to be confirmed, the findings encourage further exploration of potential treatments such as sex hormones, which may mimic pregnancy’s benefits in women with MS. The sex hormone estriol is currently in clinical trials, supported by the National MS Society and the National Institutes of Health, to treat women MS.
more news